The company will imminently start its third pivotal trial of PF-08634404.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
But the former is paying a fraction of what Merck shelled out for raludotatug.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
